Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Clinical trial NCT07140900 · RECRUITING
Trial details
- NCT number
- NCT07140900
- Sponsor
- Amgen
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-07
- Primary completion
- 2028-03-27
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.